<DOC>
	<DOC>NCT00679705</DOC>
	<brief_summary>This trial will consist of two parts: A pilot study in a three-way cross over trial to determine the highest well tolerated dose of Ritodrine (Pre-Par®), the impact of Atosiban (Tractocile®) on the hemodynamics and hence the design of the final study. The final study is planned as a three-way crossover trial to investigate and compare the cardiovascular effects of Ritodrine, Atosiban and placebo to relate those effects to the pharmacokinetics of Ritodrine and Atosiban (PK/PD modelling).</brief_summary>
	<brief_title>Influence of Tocolytical Medications on Hemodynamics (Central and Peripheral) and Vascular Function in a Pilot Study to Determine the Design of the Final Study and the Final Study Itself</brief_title>
	<detailed_description />
	<mesh_term>Atosiban</mesh_term>
	<mesh_term>Ritodrine</mesh_term>
	<mesh_term>Vasotocin</mesh_term>
	<criteria>Age between 20 and 40 years old; In good health, especially no cardiovascular diseases, obstructive lung diseases, chronic kidney diseases or diabetes mellitus. Using a proper anticonception method (orally, subcutaneously); A negative pregnancy test. Intolerance of Ritodrine; On chronic medication, except oral and subcutaneous contraception History or present presentation of cardiac arrythmias; Risk of being pregnant or less than 6 months postpartum; Giving breastfeeding; Previous uteral surgery; Using an intrauteral device (IUD); A severe addiction: nicotine (&gt; 10 cigarettes/day), alcohol (&gt; 3 units/day), caffeine (&gt; 5 units/day) or any extralegally drugs.</criteria>
	<gender>Female</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>40 Years</maximum_age>
	<verification_date>April 2009</verification_date>
	<keyword>Hemodynamics and arterial function of healthy females</keyword>
</DOC>